Annalisa Avanzati
Overview
Explore the profile of Annalisa Avanzati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Merlotti D, Rendina D, Gennari L, Mossetti G, Gianfrancesco F, Martini G, et al.
J Bone Miner Res
. 2010 Sep;
26(3):512-8.
PMID: 20814970
Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4 mg) or neridronate (200 mg) given...
2.
Gozzetti A, Gennari L, Merlotti D, Salvadori S, de Paola V, Avanzati A, et al.
Calcif Tissue Int
. 2008 Apr;
82(4):258-62.
PMID: 18418538
Nitrogen-containing bisphosphonates (N-BPs) inhibit osteoclast-mediated bone resorption and are widely used for tumor-associated osteolysis. The mechanism of action of these drugs has not been completely clarified, but it has been...
3.
Martini G, Gennari L, de Paola V, Pilli T, Salvadori S, Merlotti D, et al.
Thyroid
. 2008 Apr;
18(4):455-60.
PMID: 18399769
Objective: Recently it was found that thyrotropin (TSH) receptors are present both in osteoclast and osteoblast and that TSH can modulate bone remodeling independent of thyroid hormones. The aim of...
4.
Merlotti D, Gennari L, Martini G, Valleggi F, de Paola V, Avanzati A, et al.
J Bone Miner Res
. 2007 Jul;
22(10):1510-7.
PMID: 17605632
Unlabelled: This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15...
5.
Martini G, Gozzetti A, Gennari L, Avanzati A, Nuti R, Lauria F
Haematologica
. 2006 Dec;
91(12):1720-1.
PMID: 17145616
We evaluated the effect of zoledronic acid (ZA) on serum levels of osteoprotegerin (OPG) and the ligand for receptor activator of nuclear factor kappaB (RANKL) in patients with smoldering myeloma....
6.
Gennari L, Di Stefano M, Merlotti D, Giordano N, Martini G, Tamone C, et al.
J Bone Miner Res
. 2005 Sep;
20(10):1845-50.
PMID: 16160742
Unlabelled: We examined the prevalence of PDB in Italy from radiological, scintigraphic, and biochemical surveys in two Italian towns. Prevalence rates varied from 0.7% to 2.4%, were higher in males...
7.
Merlotti D, Gennari L, Galli B, Martini G, Calabro A, de Paola V, et al.
J Bone Miner Res
. 2005 Jul;
20(8):1356-64.
PMID: 16007333
Unlabelled: This study examined the characteristics of 147 PDB cases from Italy. Our data showed a reduced clinical severity of PDB with respect to other populations and provided further support...
8.
Nuti R, Martini G, Valenti R, Gambera D, Gennari L, Salvadori S, et al.
Clin Orthop Relat Res
. 2004 Jun;
(422):208-13.
PMID: 15187859
Hypovitaminosis D is common in elderly women. Few data are available on vitamin D status and bone turnover in women with acute hip fracture. The aims of this study were...